Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT04973033
Status
Completed

Conditions

  • ANCA Associated Vasculitis
  • Drug Use
  • JAK-STAT Pathway Deregulation

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    patients enrolled were prescribed tofacitinib 5mg twice a day orally.

Study Details

The goal of this study is to evaluate the efficacy and safety of tofacitinib 5 mg twice daily in AAV patients.

Key Dates

Start date
Dec 1, 2019
Status verified
Jul 2021
Primary completion
Jan 31, 2021
Completion
Jan 31, 2021

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofactitinib
    Tofacitinib 5mg twice a day

Primary Outcome Measure

The response rate (CR, PR and TR) [ Time Frame: From the enrollment to the end of follow-up [0 to 13 months.] ]

Related Studies